At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy of Ketamine for the Treatment of Concurrent Opioid Use Disorder and Major Depressive Disorder
In Brief
A Phase 2 clinical trial evaluating Ketamine Hydrochloride and Placebo for Depression and 2 related conditions. Completed, enrolled 21 participants across 1 site.
Detailed Summary
The purpose of the study is to examine whether an investigational medication called ketamine is able to improve treatment outcomes for concurrent opioid addiction and depression when used in conjunction with buprenorphine treatment. Study medications will be delivered twice per week for four weeks. If you are eligible and you decide to enroll in the study, your participation will last approximately 8 weeks, or 2 months.
Study Details
Timeline
Interventions
Participants receiving the active study medication will receive 60 mg ketamine twice per week for four weeks under clinical supervision.
Participants receiving the placebo study medication will receive saline twice per week for four weeks under clinical supervision.